Wikidata

(Q63814149)

English

An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Participants

clinical trial

In more languages

Statements

short name
QUEST-2 (English)
0 references
title
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety and Tolerability of TMC435 Versus Placebo as Part of a Treatment Regimen Including Peginterferon α-2a (Pegasys®) and Ribavirin (Copegus®) or Peginterferon α-2b (PegIntron®) and Ribavirin (Rebetol®) in Treatment-naïve, Genotype 1, Hepatitis C-infected Subjects (English)
0 references
medical condition
hepatitis C
0 references
hepatitis
0 references
hepatitis A
0 references
country
Argentina
0 references
Austria
0 references
Belgium
0 references
Brazil
0 references
Bulgaria
0 references
France
0 references
Germany
0 references
Netherlands
0 references
Poland
0 references
Portugal
0 references
Slovakia
0 references
Spain
0 references
Turkey
0 references
start time
March 2011
0 references
end time
February 2013
0 references
number of participants
393
0 references
minimum age
18 year
0 references

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    Retrieved from "https://www.wikidata.org/w/index.php?title=Q63814149&oldid=1857394529"